|
1. Advisory Committee on Immunization Practices. “Recommended adult immunization schedule: United States, 2010”. Ann Intern Med 2010; 152: 36.
2. Centers for Disease Control and Prevention (CDC). FDA licensure of quadrivalent human papillomavirus vaccine (HPV4, Gradasil) for use in males and guidance from the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 2010; 59: 630.
3. FUTURE II Study Group. “Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions”. N Eng J Med 2007; 356: 1915.
4. Garland SM, et al. “Quadrivalent vaccine against human papillomavirus to prevent anogenital disease”. N Eng J Med 2007; 356: 1928.
5. Hoots BE, et al. “ Human papillomavirus type distribution in anal cancer and anal intraepithelial lesions”. Int J Cancer 2009; 124: 2375.
6. Saslow D, Castle PE, Cox JT, et al. “Ameriacan Cancer Society Guideline for human papillomavirus (HPV) vaccine use to prevent cervical cancer and its precursors”. CA Cancer J Clin 2007; 57:7.
7. Slade BA, Leidel L, Vellozzi C, et al. “Postlicensure safety surveillance for quadrivalent human papillomavirus recombinant vaccine”. JAMA 2009; 302: 750.
8. Stanley M. “Immunobiology of HPV and HPV vaccines”. Gynecol Oncol 2008; 109: S15.
9. Hoàng Thị Thanh Huyền, “Xác định tỷ lệ nhiễm và genotype của Human papillomavirus trên gái mại dâm tại Hải Phòng, Việt Nam” – luận văn tiến sĩ Hoá sinh y học.
10. Lê Trung Thọ, Trần Văn Hợp, “Nghiên cứu tỷ lệ nhiễm HPV ở cộng đồng phụ nữ Hà Nội, tìm hiểu một số yếu tố liên quan” – Tạp chí Y học TP Hồ Chí Minh, vol 13, N1 supl, 2009, 185-189.
11. Bosch FX, Burchell AN, Schiffman M, et al. Epidemiology and natural history of human papillomavirus infections and type-specific implications in cervical neoplasia. Vaccine. 2008;26(suppl 10):K1–K16.
12. Wen LM, Estcourt CS, Simpson JM, Mindel A. Risk factors for the acquisition of genital warts: are condoms protective? Sex Transm Infect. 1999;75(5):312–316.
13. Khan AM, Freeman-Wang T, Pisal N, Singer A. Smoking and multicentric vulval intraepithelial neoplasia. J Obstet Gynaecol. 2009;29(2):123–125.
14. Maucort-Boulch D, Plummer M, Castle PE, et al. Predictors of human papillomavirus persistence among women with equivocal or mildly abnormal cytology. Int J Cancer. 2010;126(3):684–691.
15. Paavonen J, Naud P, Salmerón J, et al.; HPV PATRICIA Study Group. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet. 2009;374(9686):301–314.
16. Garland SM, Hernandez-Avila M, Wheeler CM, et al.; Females United to Unilaterally Reduce Endo/Ectocervical Disease (FUTURE) I Investigators. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med. 2007;356(19):1928–1943.
17. FUTURE II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions N Engl J Med. 2007;356(19):1915–1927.
18. Ridzon R, Singh K. Male circumcision for the prevention of HSV-2 and HPV infections. N Engl J Med. 2009;361(3):307.
19. Division of STD Prevention (1999). Prevention of genital HPV infection and sequelae: report of an external consultants' meeting. Atlanta, GA: Centers for Disease Control and Prevention. Retrieved December 27, 2011.
20. Winer RL, Hughes JP, Feng Q, et al. Condom use and the risk of genital human papillomavirus infection in young women. New England Journal of Medicine 2006; 354(25):2645–2654. [PubMed Abstract]
21. Chaturvedi AK, Engels EA, Pfeiffer RM, et al. Human papillomavirus and rising oropharyngeal cancer incidence in the United States. Journal of Clinical Oncology 2011; 29(32):4294–4301. [PubMed Abstract]
22. de Martel C, Ferlay J, Franceschi S, et al. Global burden of cancers attributable to infections in 2008: A review and synthetic analysis. Lancet Oncology 2012; 13(6):607-615. [PubMed Abstract]
23. Jemal A, Simard EP, Dorell C, et al. Annual Report to the Nation on the Status of Cancer, 1975-2009, featuring the burden and trends in human papillomavirus (HPV)-associated cancers and HPV vaccination coverage levels. Journal of the National Cancer Institute 2013; 105(3):175-201. [PubMed Abstract].
24. Winer RL HJ, Feng Q, et al. Condom use and the risk of genital human papillomavirus infection in young women. N Engl J Med. 2006;354(25):2645–2654.
25. Wen LM EC, Simpson JM, Mindel A. Risk factors for the acquisition of genital warts: are condoms protective? Sex Transm Infect. 1999;75(5):312–316.
26. Burchell AN WR, de Sanjosé S, Franco EL. Chapter 6: epidemiology and transmission dynamics of genital HPV infection. Vaccine. 2006;24(suppl 3):S3/52–S3/61.
27. Khan AM F-WT, Pisal N, Singer A. Smoking and multicentric vulval intraepithelial neoplasia. J Obstet Gynaecol. 2009;29(2):123–125.
28. Maucort-Boulch D PM, Castle PE, et al. Predictors of human papillomavirus persistence among women with equivocal or mildly abnormal cytology. Int J Cancer. 2010;126(3):684–691.
29. Mejlhede N BJ, Fomsgaard A. High frequency of multiple HPV types in cervical specimens from Danish women. APMIS. 2009;117(2):108–114.
30. Ho GY BR, Beardsley L, Chang CJ, Burk RD. Natural history of cervicovaginal papillomavirus infection in young women. N Engl J Med. 1998;338(7):423–428.
31. Koshiol J LL, Pimenta JM, Poole C, Jenkins D, Smith JS. Persistent human papillomavirus infection and cervical neoplasia: a systematic review and meta-analysis. Am J Epidemiol. 2008;168(2):123–137.
32. Winer RL KN, Hughes JP, et al. Development and duration of human papillomavirus lesions, after initial infection. J Infect Dis. 2005;191(5):731–738.
33. Lacey CJ. Therapy for genital human papillomavirus-related disease. J Clin Virol. 2005;32(suppl 1):S82–S90.
34. Moscicki AB EJ, Farhat S, Xu J. Persistence of human papillomavirus infection in HIV-infected and -uninfected adolescent girls: risk factors and differences, by phylogenetic type. J Infect Dis. 2004;190(1):37–45.
35. ACOG Committee on Practice Bulletins--Gynecology APBnCcsOG, 2009: p. 114:1409.
36. Stoler MH CP, Solomon D, Schiffman M; American Society for Colposcopy and Cervical Pathology. The expanded use of HPV testing in gynecologic practice per ASCCP-guided management requires the use of well-validated assays. Am J Clin Pathol. 2007;127(3):335–337.
37. Cox JT MA, Castle PE. Commentary on: statement on HPV DNA test utilization. J Low Genit Tract Dis. 2009;13(3):131–134.
38. Wright TC Jr ML, Dunton CJ, Spitzer M, Wilkinson EJ, Solomon D; 2006 American Society for Colposcopy and Cervical Pathologysponsored Consensus Conference. 2006 consensus guidelines for the management of women with abnormal cervical cancer screening tests. Am J Obstet Gynecol. 2007;197(4):346–355.
|
